公开(公告)号：US20240262902A1

公开(公告)日：2024-08-08

申请号：US18403043

申请日：2024-01-03

申请人： MedImmune Limited

发明人： Darren Schofield ,  Matthew Alexander Sleeman ,  Iain Patrick Chessell ,  Jonathan Hatcher ,  David Lowe

IPC分类号： C07K16/22 ,  A61K39/00 ,  C07K14/48 ,  C07K14/705 ,  C07K14/715

CPC分类号： C07K16/22 ,  C07K14/48 ,  C07K14/70578 ,  C07K14/7151 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/35

摘要： This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNFα antagonist. The NGF antagonist and the TNFα antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNFα antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNFα antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNFα antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNFα antagonist administered alone.

公开(公告)号：US11999794B2

公开(公告)日：2024-06-04

申请号：US16750951

申请日：2020-01-23

申请人： Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： Gregory Beatty ,  Boris Engels ,  Neeraja Idamakanti ,  Carl H. June ,  Andreas Loew ,  Huijuan Song ,  Qilong Wu

IPC分类号： C07K16/30 ,  A61K31/436 ,  A61K38/00 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61K48/00 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/85 ,  C12N15/86

CPC分类号： C07K16/30 ,  A61K31/436 ,  A61K38/1774 ,  A61K38/1793 ,  A61K39/001168 ,  A61K39/39558 ,  A61K48/0058 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/7151 ,  C07K16/303 ,  C07K16/3061 ,  C07K16/3069 ,  C12N5/0638 ,  C12N15/85 ,  C12N15/86 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/5158 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/74 ,  C12N2740/15041

摘要： Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.

公开(公告)号：US11952399B2

公开(公告)日：2024-04-09

申请号：US16708987

申请日：2019-12-10

申请人： AMGEN INC.

发明人： Ashish Sharma ,  Balakumar Thangaraj

IPC分类号： C07K1/20 ,  C07K14/715

CPC分类号： C07K1/20 ,  C07K14/7151 ,  C07K2319/30

摘要： The invention pertains to methods of purifying fusion proteins, in particular TNFR:Fc fusion proteins. Methods disclosed herein can be used to produce highly pure TNFR:Fc fusion proteins (e.g., etanercept) having a biological activity by removing hard to separate product related impurities such as clipped and/or mis-fold/aggregated TNFR:Fc fusion proteins.

公开(公告)号：US20240050567A1

公开(公告)日：2024-02-15

申请号：US18260562

申请日：2022-01-04

申请人： SHANGHAI JIAO TONG UNIVERSITY

发明人： Xuanming YANG ,  Haiyong WANG

IPC分类号： A61K39/00 ,  C07K14/725 ,  C07K14/47 ,  C07K16/28 ,  C07K14/705 ,  C07K14/735 ,  C07K14/715 ,  A61P35/00

CPC分类号： A61K39/4631 ,  C07K14/7051 ,  C07K14/4747 ,  C07K16/2887 ,  C07K16/28 ,  C07K14/70521 ,  C07K14/70517 ,  C07K14/70596 ,  C07K14/70535 ,  C07K14/7056 ,  C07K14/70589 ,  C07K14/70532 ,  C07K14/7151 ,  C07K14/70575 ,  A61P35/00 ,  C07K2317/622 ,  C07K2319/03

摘要： An immune effector cell, including and/or expressing a chimeric antigen receptor (CAR), and a Bcl-2 protein or a functionally active fragment thereof. A composition including the immune effector cell. A method for treating diseases and/or disorders, including administering to a subject in need thereof the immune effector cell, where the diseases and/or disorders include tumors.

公开(公告)号：US11897949B2

公开(公告)日：2024-02-13

申请号：US17333291

申请日：2021-05-28

申请人： MedImmune Limited

发明人： Darren Schofield ,  Matthew Alexander Sleeman ,  Iain Patrick Chessell ,  Jonathan Hatcher ,  David Lowe

IPC分类号： C07K16/22 ,  C07K14/705 ,  C07K14/18 ,  A61K39/00 ,  C07K14/715 ,  C07K14/48

CPC分类号： C07K16/22 ,  C07K14/48 ,  C07K14/70578 ,  C07K14/7151 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/35

摘要： This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNFα antagonist. The NGF antagonist and the TNFα antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNFα antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNFα antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNFα antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNFα antagonist administered alone.

公开(公告)号：US20240018206A1

公开(公告)日：2024-01-18

申请号：US17927625

申请日：2020-07-09

申请人： BEIJING VDJBIO CO., LTD.

发明人： Ziqiang LI ,  Rong MA ,  Xinsheng TIAN ,  Yiping SUN ,  Yiren LIU ,  Shaokui LI

IPC分类号： C07K14/545 ,  C07K14/715 ,  C07K14/79 ,  C07K14/765

CPC分类号： C07K14/545 ,  C07K14/7151 ,  C07K14/79 ,  C07K14/765 ,  C07K2319/30 ,  A61K38/00

摘要： Provided is an Interleukin-1 Receptor Antagonist (IL-1RN) protein or a variant or analogue thereof, and a fusion protein comprising the following three-parts: the Interleukin-1 Receptor Antagonist protein or a variant or analogue thereof, a domain for half-life extension and an optional tumor necrosis factor receptor 2, and the preparation method and use thereof. The above-mentioned protein mutant and fusion protein have the effects of extended half-life, improved affinity with interleukin-1 receptor and superior biological activity, and find use in the field of treatment and prevention of inflammatory-associated diseases.

公开(公告)号：US11834491B2

公开(公告)日：2023-12-05

申请号：US17216769

申请日：2021-03-30

申请人： Biogen MA Inc.

发明人： Kevin Maloney ,  Ke Gong ,  Roy Alston

IPC分类号： A61K38/17 ,  A61K47/68 ,  A61K9/00 ,  A61K47/26 ,  A61K47/02 ,  C07K19/00 ,  C07K14/715 ,  A61P29/00 ,  C07K14/705 ,  C07K14/525 ,  C07K16/24

CPC分类号： C07K14/7151 ,  A61K9/0019 ,  A61K38/1793 ,  A61K47/26 ,  A61K47/68 ,  C07K19/00 ,  A61K47/02 ,  A61P29/00 ,  C07K14/525 ,  C07K14/70578 ,  C07K16/241 ,  C07K2319/30

摘要： Aspects of the invention are directed to arginine-free polypeptide-containing compositions and methods for treating disorders associated with inflammation or the autoimmune response. In particular, the polypeptide is etanercept.

公开(公告)号：US20230181634A1

公开(公告)日：2023-06-15

申请号：US16617487

申请日：2018-05-31

申请人： Pfizer Inc.

发明人： Barbra Johnson SASU ,  Danielle Elizabeth DETTLING ,  Cesar Adolfo SOMMER ,  Yik Andy YEUNG ,  Moustafa Marc HAMZE

IPC分类号： A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C07K14/705 ,  C07K14/715 ,  A61K39/395 ,  A61K45/06 ,  A61P35/02

CPC分类号： A61K35/17 ,  C07K14/7051 ,  C07K16/2863 ,  C07K14/70517 ,  C07K14/7151 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/02 ,  C07K2317/622 ,  A61K38/00

摘要： Provided herein are antibodies that specifically bind to Fms-like tyrosine kinase 3 (FLT3), chimeric antigen receptors (CARs) that specifically bind to FLT3, and engineered immune cells expressing such CARs (e.g. FLT3-specific CAR-T cells). The invention also provides making such antibodies, CARs, and engineered immune cells. The invention also provides using such antibodies, CARs, and engineered immune cells, for example for the treatment of a condition associated with malignant cells expressing FLT3 (e.g., cancer).

公开(公告)号：US20230172982A1

公开(公告)日：2023-06-08

申请号：US17795735

申请日：2020-01-30

申请人： ImmunityBio, Inc.

发明人： Laurent H. Boissel ,  Hans G. Klingemann ,  Barry J. Simon, M.D. ,  Abhijit Dandapat

IPC分类号： A61K35/17 ,  C07K14/495 ,  C07K14/54 ,  C07K14/735 ,  C07K14/715 ,  C07K14/725 ,  C07K14/55

CPC分类号： A61K35/17 ,  C07K14/495 ,  C07K14/5434 ,  C07K14/70535 ,  C07K14/7151 ,  C07K14/7051 ,  C07K14/55 ,  C07K14/5443 ,  C07K2317/622 ,  C07K2317/53

摘要： Provided are genetically modified NK cells expressing a chimeric antigen receptor targeting an BCMA superfamily receptor. The CAR can comprise an intracellular domain of FcεRIγ and further recombinant proteins expressed by the genetically modified NK cells are CD16, autocrine growth stimulating cytokines, and optionally one of IL-12, a TGF-beta trap, or a homing receptor. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient the genetically modified NK cells.

公开(公告)号：US20190194291A1

公开(公告)日：2019-06-27

申请号：US16184147

申请日：2018-11-08

申请人： Hoffmann-La Roche Inc.

发明人： Peter Bruenker ,  Claudia Ferrara Koller ,  Sandra Grau-Richards ,  Christian Klein ,  Ekkehard Moessner ,  Pablo Umana ,  Maria Amann ,  Christina Claus ,  Wei Xu

IPC分类号： C07K14/705 ,  C07K16/40 ,  C07K16/28 ,  C07K16/30

CPC分类号： C07K14/70578 ,  A61K39/395 ,  A61K47/6813 ,  A61K47/6835 ,  C07K14/70575 ,  C07K14/7151 ,  C07K16/14 ,  C07K16/241 ,  C07K16/2803 ,  C07K16/3007 ,  C07K16/40 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/92 ,  C07K2319/30

摘要： The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) one Fab domain capable of specific binding to a target cell antigen, (b) a Fc domain composed of a first and a second subunit capable of stable association, and (c) a first polypeptide comprising two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and a second polypeptide comprising one ectodomain of said TNF ligand family member or a fragment thereof, wherein the first polypeptide is fused at its N-terminus to the C-terminus of one of the subunits of the Fc domain and wherein the second polypeptide is fused at its N-terminus to the C-terminus of the other subunit of the Fc domain, wherein the TNF family ligand trimer-containing antigen binding molecule is monovalent for the binding to the target cell antigen.